- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Study finds personalized antibiotics, prebiotics, and probiotics combo may help treat IBS - Video
|
Overview
A study presented at the European Society of Clinical Microbiology and Infectious Diseases conference revealed that over a third of patients treated with a precision approach to post-infectious irritable bowel syndrome (IBS) reported improved symptoms 12 weeks after starting treatment.
IBS is a chronic condition that affects a person’s digestive system. Symptoms include recurrent pain and changes to bowel habits.
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, gas, diarrhea, and constipation. It is a chronic condition that affects the large intestine and can significantly impact a person's quality of life. While the exact cause of IBS is not fully understood, it is believed to involve a combination of factors including abnormal gastrointestinal motility, increased sensitivity to certain foods, stress, and alterations in the gut microbiota.
In the study, researchers recruited 13 participants and prescribed a specific regime of one of two antibiotics to treat pathogenic bacteria that existed at levels that were too high, as well as probiotics to replace beneficial strains that were at levels that were too low. Prebiotics including inulin and psyllium were prescribed to over two-thirds of participants.
After 12 weeks of treatment initiation, 12 out of 13 participants showed symptom improvement. Initially reported symptoms included abdominal pain, bloating, diarrhea, constipation, weight loss, and dyspepsia. Following treatment, the predominant symptoms were abdominal pain, bloating, and diarrhea. Additionally, five participants achieved complete symptom remission.
“As there is significant variation between even healthy individuals’ microbiome, it was unclear whether the dysbiosis — the imbalance between different bacterial strains in the gut — that occurs in people with post-infectious IBS had caused the symptoms they experienced. People should have their microbiomes sequenced when they are healthy for research in this area to advance, and causal factors to be identified. If we can get to that stage, I think we will truly practice personalized medicine, and we can get much better in targeting treatments with some of these antibiotics, probiotics, or prebiotics,” explained Satish Rao, gastroenterologist and professor of medicine at the Medical College of Georgia, Augusta University.
Reference: European Society of Clinical Microbiology and Infectious Diseases conference: Barcelona, Spain- 27-30 April; Can a personalized antibiotics, prebiotics, and probiotics combo help treat IBS?
Speakers
Anshika Mishra is a dedicated scholar pursuing a Masters in Biotechnology, driven by a profound passion for exploring the intersection of science and healthcare. Having embarked on this academic journey with a passion to make meaningful contributions to the medical field, Anshika joined Medical Dialogues in 2023 to further delve into the realms of healthcare journalism.